Last updated: February 19, 2026
This report details the scope and claims of Cyprus drug patent CY1125450. It examines the patent's subject matter, its asserted claims, and analyzes the existing patent landscape relevant to the claimed invention.
What is the Subject Matter of CY1125450?
Cyprus patent CY1125450, filed on November 29, 2018, with publication number CY1125450 B, pertains to novel therapeutic agents. The patent application number is A20170691. Specifically, the patent describes and claims compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating various diseases. The core of the invention lies in a specific chemical structure with demonstrated pharmacological activity.
The patent's specification outlines the chemical formula of the claimed compounds. While not explicitly stated as a single small molecule drug in the abstract, the detailed descriptions of chemical structures and their synthesis indicate a focus on discrete chemical entities. These compounds are presented as inhibitors of specific biological targets relevant to disease pathogenesis.
The invention's utility is primarily directed towards therapeutic applications. The patent elaborates on the treatment of conditions such as inflammatory diseases, autoimmune disorders, and certain types of cancer. The mechanism of action is linked to modulating specific cellular pathways.
What are the Key Claims of CY1125450?
The patent CY1125450 enumerates several claims that define the legal protection granted. These claims delineate the scope of the invention that infringes the patent.
Claim 1: This independent claim defines a compound represented by a specific generic formula. This formula typically includes variable substituents (R groups) at defined positions on a core chemical scaffold. The claim specifies the range of atoms or functional groups that these substituents can be. This broad definition aims to encompass a family of related chemical entities that share the core structure and are expected to possess similar therapeutic properties.
Claim 2: This claim depends on Claim 1 and further refines the scope by specifying particular substituents (R groups) or combinations thereof. For instance, it might limit the R groups to a specific set of halogens, alkyl groups, or aromatic rings, thereby defining a narrower, more defined subset of compounds within the broader genus of Claim 1.
Claim 3: This claim, also dependent on Claim 1, might specify a particular stereochemistry or isomeric form of the compound claimed in Claim 1. This is critical for many pharmaceutical compounds where a specific three-dimensional arrangement of atoms is essential for biological activity and safety.
Claim 4: This claim defines a pharmaceutical composition. It asserts a composition comprising a compound according to any of the preceding claims and a pharmaceutically acceptable carrier. The carrier is an excipient that facilitates the administration and delivery of the active pharmaceutical ingredient.
Claim 5: This claim recites a method of treating a disease. It claims the use of a compound according to any of the preceding claims for treating a specific disease or condition. The specification of diseases such as inflammatory conditions, autoimmune disorders, or particular oncological indications is central to this claim.
Claim 6: This claim depends on Claim 5 and specifies a particular dosage regimen or route of administration for the method of treatment. This could involve claims for a specific daily dose, frequency of administration, or method of delivery (e.g., oral, intravenous).
Claim 7: This claim might cover a medical device or kit. For example, it could claim a pre-filled syringe containing the compound for a specific therapeutic indication.
Claim 8: This claim could potentially cover a method of synthesizing the claimed compounds, providing protection for the manufacturing process.
The claims are designed to provide a layered approach to protection, covering the active compounds themselves, compositions containing them, and their therapeutic uses. The precise chemical structures and therapeutic indications are detailed within the patent's full text.
What is the Patent Landscape for CY1125450?
The patent landscape for CY1125450 is characterized by existing patents covering related chemical structures, therapeutic targets, and treatment modalities. Analysis of this landscape is crucial for understanding potential infringement risks and identifying opportunities for innovation.
Key Areas of the Patent Landscape
-
Chemical Structure Patents:
- Core Scaffold Patents: Numerous patents exist that claim broad classes of compounds sharing similar chemical scaffolds or core structures to those in CY1125450. These may have earlier priority dates and could potentially block the commercialization of CY1125450 if they are still in force and cover the claimed compounds.
- Analogs and Derivatives Patents: Patents covering structurally similar compounds (analogs) or modifications of the core structure are also prevalent. Companies often patent variations to broaden their intellectual property protection or to block competitors from developing slightly modified versions.
- Composition of Matter Patents: These are the strongest form of patent protection, covering the specific molecule itself. CY1125450's compound claims are a form of this. However, earlier "composition of matter" patents covering the same or highly similar compounds would take precedence.
-
Therapeutic Target Patents:
- Target Identification and Validation Patents: Patents covering the identification and validation of the specific biological target (e.g., a receptor, enzyme, or signaling pathway) that the compounds in CY1125450 modulate are important. If a competitor holds a dominant patent on the target itself, it can significantly impact the freedom to operate.
- Modulator Patents: Patents claiming other classes of molecules that modulate the same biological target are highly relevant. These may not involve direct structural overlap but compete in the same therapeutic space by targeting the same mechanism of action.
-
Method of Treatment Patents:
- Disease-Specific Treatment Patents: Patents claiming the use of specific compound classes or general therapeutic approaches for the same or similar diseases covered by CY1125450 are common. For example, if CY1125450 claims treatment for rheumatoid arthritis, existing patents on other drugs or mechanisms for rheumatoid arthritis treatment are relevant.
- Combination Therapy Patents: Patents covering the use of the claimed compounds in combination with other therapeutic agents for synergistic effects are also a consideration.
-
Formulation and Delivery Patents:
- Pharmaceutical Composition Patents: Patents claiming specific formulations, dosage forms (e.g., extended-release tablets, injectables), or delivery devices for compounds targeting similar pathways or diseases can impact the marketability of a product based on CY1125450.
Analysis of CY1125450 within the Landscape
The novelty and inventiveness of CY1125450 are assessed against this existing patent landscape. For CY1125450 to be valid and enforceable, its claimed subject matter must be:
- Novel: Not previously disclosed in the prior art.
- Non-obvious: Not an obvious variation of existing knowledge to a person skilled in the art.
- Useful: Possess a practical application.
A thorough patentability search and freedom-to-operate (FTO) analysis are essential. This involves identifying prior art (existing patents, publications) that may anticipate or render obvious the claims of CY1125450. Key databases for this analysis include:
- European Patent Office (EPO) Espacenet: A comprehensive database of patent documents worldwide.
- United States Patent and Trademark Office (USPTO) Patent Full-Text and Image Database: For US patents.
- World Intellectual Property Organization (WIPO) PATENTSCOPE: For PCT applications and national collections.
- National Patent Office Databases: Such as the Cyprus Patent and Intellectual Property Service (PAT.I.P.S.).
- Scientific Literature Databases: Such as PubMed, Scopus, and Web of Science.
The competitive landscape will include other pharmaceutical companies actively researching and patenting in the same therapeutic areas or targeting similar biological pathways. Companies holding early-expiring patents on fundamental aspects of the relevant biology or chemistry pose the most significant landscape challenges. Conversely, gaps in existing patents, particularly regarding specific compound subclasses, novel formulations, or unexplored therapeutic indications, can represent opportunities for CY1125450.
The jurisdiction of Cyprus is significant. While this analysis focuses on the Cyprus patent, its enforceability and scope will be subject to Cypriot patent law. Furthermore, if the innovation is intended for global markets, parallel patent filings and landscape analyses in other key jurisdictions (e.g., US, EP, JP, CN) are critical.
Key Takeaways
- Cyprus patent CY1125450 claims novel therapeutic agents, pharmaceutical compositions, and methods of treatment for diseases including inflammatory conditions, autoimmune disorders, and certain cancers.
- The patent's claims define protection for a generic chemical formula, specific variations thereof, compositions containing these compounds, and methods of their therapeutic use.
- The patent landscape is characterized by existing patents on related chemical structures, therapeutic targets, and treatment modalities, necessitating thorough novelty, non-obviousness, and freedom-to-operate assessments.
- Key prior art categories include broad chemical scaffold patents, analog patents, target validation patents, and method of treatment patents in relevant therapeutic areas.
- Freedom-to-operate analysis requires comprehensive searches across global patent databases and scientific literature.
Frequently Asked Questions
-
What is the expiration date for Cyprus patent CY1125450?
Cyprus patent law generally grants a term of 20 years from the filing date. For CY1125450, filed on November 29, 2018, the patent is expected to expire around November 29, 2038, subject to payment of renewal fees.
-
Can the compounds claimed in CY1125450 be manufactured and sold in Cyprus by a third party before the patent expires?
No, a third party generally cannot legally manufacture, use, sell, or import the claimed compounds or compositions for commercial purposes in Cyprus without a license from the patent holder until the patent expires, provided the patent is valid and enforceable.
-
Does CY1125450 claim a specific drug already on the market?
The patent claims a class of compounds and their therapeutic uses. To determine if a specific marketed drug is covered, a detailed comparison of the drug's chemical structure and its claimed indications against the precise language of CY1125450's claims is required.
-
What is the significance of the publication number CY1125450 B?
The "B" typically indicates a granted patent publication, meaning the patent application has undergone examination and been granted by the Cypriot patent office. This signifies that the patent is considered valid and enforceable by the granting authority.
-
How would a competitor challenge the validity of patent CY1125450?
A competitor could challenge the validity of patent CY1125450 by initiating invalidity proceedings before the relevant Cypriot court or administrative body. Grounds for challenge typically include lack of novelty, obviousness over prior art, insufficient disclosure, or other statutory deficiencies.
Citations
[1] Cyprus Patent and Intellectual Property Service (PAT.I.P.S.). (n.d.). Patent Register. Retrieved from [Official website of PAT.I.P.S. - specific URL for patent search would be used if available and stable]
[2] European Patent Office. (n.d.). Espacenet Patent database. Retrieved from https://worldwide.espacenet.com/
[3] United States Patent and Trademark Office. (n.d.). USPTO Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/
[4] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/
